Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1985-5-30
|
pubmed:grant | |
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Acquired Immunodeficiency Syndrome,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research,
http://linkedlifedata.com/resource/pubmed/keyword/Diseases,
http://linkedlifedata.com/resource/pubmed/keyword/Examinations And Diagnoses,
http://linkedlifedata.com/resource/pubmed/keyword/Hiv Infections,
http://linkedlifedata.com/resource/pubmed/keyword/Laboratory Examinations And Diagnoses,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Viral Diseases
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0077-8923
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
437
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
88-99
|
pubmed:dateRevised |
2007-11-15
|
pubmed:otherAbstract |
PIP: The adnormal levels of thymosin alpha 1 in acquired immunodeficiency syndrome (AIDS) patients, depressed T-cell function, thymus pathology, and the restoration of T-cell function by thymosin fraction 5 (TF5) lend support to the hypothesis that the thymus plays a central role in AIDS. The thymosin alpha 1 assay may provide a means of identifying symptomatic carriers of AIDS. This paper summarizes the current status of diagnostic studies with thymosin alpha 1 in AIDS and reports the 1st clinical trial with thymosin in subjects with AIDS-like immune dysfunction. Serum samples from intravenous drug abusers, homosexuals, and Haitians with AIDS have revealed thymosin alpha 1 levels at least 2 standard deviations from the mean of controls without AIDS. Preliminary data from a pilot study in homosexuals and hemophiliacs at high risk for AIDS suggest that the administration of TF5 may be effective in reconstituting some T-cell mediated specific immune functions, including cell-medicated lympholysis (CML) and the mixed lymphocyte response (MLR), and enhancing the lectin-induced production of T-cell growth factor. On the other hand, TF5 has failed to have any effects on the T4/T8 ratio, absolute lymphocyte counts, or natural killer cell activity.
|
pubmed:meshHeading |
pubmed-meshheading:6398657-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:6398657-Adult,
pubmed-meshheading:6398657-Aged,
pubmed-meshheading:6398657-Clinical Trials as Topic,
pubmed-meshheading:6398657-Female,
pubmed-meshheading:6398657-Hemophilia A,
pubmed-meshheading:6398657-Homosexuality,
pubmed-meshheading:6398657-Humans,
pubmed-meshheading:6398657-Interleukin-2,
pubmed-meshheading:6398657-Male,
pubmed-meshheading:6398657-Middle Aged,
pubmed-meshheading:6398657-Pilot Projects,
pubmed-meshheading:6398657-Pneumonia, Pneumocystis,
pubmed-meshheading:6398657-Risk,
pubmed-meshheading:6398657-Sarcoma, Kaposi,
pubmed-meshheading:6398657-Thymosin
|
pubmed:year |
1984
|
pubmed:articleTitle |
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|